Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022
Yonatan M. Mefsin, Dongxuan Chen, Helen S. Bond, Yun Lin, Justin K. Cheung, Jessica Y. Wong, Sheikh Taslim Ali, Eric H.Y. Lau, Peng Wu
, Gabriel M. Leung, and Benjamin J. Cowling
Author affiliations: World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China (Y.M. Mefsin, D. Chen, H.S. Bond, Y. Lin, J.K. Cheung, J.Y. Wong, S.T. Ali, E.H.Y. Lau, P. Wu, G.M. Leung, B.J. Cowling); Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong (D. Chen, S.T. Ali, E.H.Y. Lau, P. Wu, G.M. Leung, B.J. Cowling)
Main Article
Figure 2
Figure 2. Age-stratified estimates of the case-fatality risk for COVID-19 in epidemic waves 1–4 and wave 5 in Hong Kong by vaccination status. Case-patients were classified as having a complete primary series if they had received >2 doses of COVID-19 vaccines >2 weeks before symptom onset (for symptomatic case-patients) or >3 weeks before laboratory confirmation of the infection (for symptomatic case-patients with a missing onset date or asymptomatic case-patients), otherwise as having an incomplete primary series. The COVID-19 vaccines available in Hong Kong included BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) and CoronaVac (Sinovac, https://www.sinovac.com) vaccines.
Main Article
Page created: June 22, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.